{{Drugbox
| Watchedfields = changed
| verifiedrevid = 460781978
| IUPAC_name = 7-Chloro-3-methyl-4''H''-1,2,4-benzothiadiazine 1,1-dioxide
| image = Diazoxide Structural Formula V.1.svg
<!--Clinical data-->
| tradename = Proglycem
| Drugs.com = {{drugs.com|monograph|diazoxide}}
| pregnancy_AU = C
| pregnancy_US = C
| legal_UK = POM
| legal_US = Rx-only
| routes_of_administration = Oral, [[Intravenous therapy|intravenous]]
<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound = 90%
| metabolism = [[Liver|Hepatic]] [[oxidation]] and [[sulfate]] conjugation
| elimination_half-life = 21-45 hours
| excretion = [[Kidney|Renal]]
<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}} 
| CAS_number = 364-98-7
| ATC_prefix = C02
| ATC_suffix = DA01
| ATC_supplemental =  {{ATC|V03|AH01}}
| PubChem = 3019
| IUPHAR_ligand = 2409
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB01119
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 2911
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = O5CB12L4FN
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00294
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 4495
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 181
<!--Chemical data-->
| C=8 | H=7 | Cl=1 | N=2 | O=2 | S=1
| molecular_weight = 230.672 g/mol
| smiles = Clc1ccc2c(c1)S(=O)(=O)/N=C(\N2)C
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C8H7ClN2O2S/c1-5-10-7-3-2-6(9)4-8(7)14(12,13)11-5/h2-4H,1H3,(H,10,11)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = GDLBFKVLRPITMI-UHFFFAOYSA-N
}}

'''Diazoxide''' ([[International Nonproprietary Name|INN]]; brand name '''Proglycem'''<ref>[http://www.drugs.com/cons/diazoxide.html Diazoxide], drugs.com</ref>) is a [[potassium channel]] activator, which causes local relaxation in [[smooth muscle]] by increasing membrane [[Semipermeable membrane|permeability]] to potassium [[ion]]s. This switches off voltage-gated [[calcium]] ion channels, preventing calcium flux across the sarcolemma and activation of the contractile apparatus.

In the United States, this agent is typically given in hospital.<ref name=":0">{{Cite press release|title = FDA Drug Safety Communication: FDA warns about a serious lung condition in infants and newborns treated with Proglycem (diazoxide)|date = July 16, 2015|publisher = [[USFDA|Food and Drug Administration]]|url = http://www.fda.gov/Drugs/DrugSafety/ucm454833.htm|access-date = 2015-07-19}}</ref>

==Medical uses==
Diazoxide is used as a [[vasodilator]] in the treatment of acute [[hypertension]] or [[malignant hypertension]].<ref name="pmid8884561">{{cite journal |vauthors=van Hamersvelt HW, Kloke HJ, de Jong DJ, Koene RA, Huysmans FT |title=Oedema formation with the vasodilators nifedipine and diazoxide: direct local effect or sodium retention? |journal=[[J. Hypertens.|Journal of Hypertension]] |volume=14 |issue=8 |pages=1041–5 |date=August 1996 |pmid=8884561 |doi= 10.1097/00004872-199608000-00016 }}{{closed access}}</ref>

Diazoxide also inhibits the secretion of [[insulin]] from the pancreas, thus it is used to counter hypoglycemia in disease states such as [[insulinoma]] (a tumor producing insulin)<ref name="pmid17053028">{{cite journal |vauthors=Huang Q, Bu S, Yu Y |title=Diazoxide prevents diabetes through inhibiting pancreatic beta-cells from apoptosis via Bcl-2/Bax rate and p38-beta mitogen-activated protein kinase |journal=Endocrinology |volume=148 |issue=1 |pages=81–91 |date=January 2007 |pmid=17053028 |doi=10.1210/en.2006-0738 |url=http://endo.endojournals.org/cgi/pmidlookup?view=long&pmid=17053028|display-authors=etal}}{{open access}}</ref> or [[congenital hyperinsulinism]].

Diazoxide acts as a positive [[allosteric]] modulator of the [[AMPA receptor|AMPA]] and [[kainate receptor]]s, suggesting potential application as a cognitive enhancer.<ref>{{Cite journal |last=Randle |first=John C.R. |last2=Biton |first2=Catherine |first3=Jean M. |last3=Lepagnol |title=Allosteric potentiation by diazoxide of AMPA receptor currents and synaptic potentials |date=15 November 1993 |pages=257–65 |volume=247 |issue=3 |journal=[[Eur. J. Pharmacol.|European Journal of Pharmacology]] |pmid=8307099 |doi=10.1016/0922-4106(93)90193-D }}{{closed access}}</ref>

==Side effects==
{{Refimprove|date = July 2015}}

Diazoxide interferes with insulin release through its action on potassium channels.<ref>{{Cite journal|title = Control of insulin secretion by sulfonylureas, meglitinide and diazoxide in relation to their binding to the sulfonylurea receptor in pancreatic islets|url = http://www.sciencedirect.com/science/article/pii/0006295289903274|journal = Biochemical Pharmacology|date = 1989-04-15|pages = 1217–1229|volume = 38|issue = 8|doi = 10.1016/0006-2952(89)90327-4|first = Uwe|last = Panten|first2 = Johanna|last2 = Burgfeld|first3 = Frank|last3 = Goerke|first4 = Michael|last4 = Rennicke|first5 = Mathias|last5 = Schwanstecher|first6 = Andreas|last6 = Wallasch|first7 = Bernd J.|last7 = Zünkler|first8 = Sigurd|last8 = Lenzen}}</ref> Diazoxide is one of the most potent openers of the K+ ATP channels present on the insulin producing beta cells of the pancreas. Opening these channels leads to hyperpolarization of cell membrane, a decrease in calcium influx, and a subsequently reduced release of insulin.<ref>{{Cite journal|title = Pharmacological Agents That Directly Modulate Insulin Secretion|url = http://pharmrev.aspetjournals.org/content/55/1/105|journal = Pharmacological Reviews|date = 2003-03-01|issn = 1521-0081|pmid = 12615955|pages = 105–131|volume = 55|issue = 1|doi = 10.1124/pr.55.1.7|language = en|first = Máire E.|last = Doyle|first2 = Josephine M.|last2 = Egan}}</ref> This mechanism of action is the mirror opposite of that of [[sulfonylurea]]s, a class of medications used to increase insulin release in [[Diabetes mellitus type 2|Type 2 Diabetics]]. Therefore, this medicine is not given to non-insulin dependent diabetic patients.

The [[USFDA|Food and Drug Administration]] published a Safety Announcement in July 2015 highlighting the potential for development of [[pulmonary hypertension]] in newborns and infants treated with this drug.<ref name=":0" />

==See also==
* [[Hydrochlorothiazide]] (HCTZ)
* [[AMPA receptor positive allosteric modulator]]

==References==
{{Reflist|2}}

{{Nonsympatholytic vasodilatory antihypertensives}}
{{Other therapeutic products}}
{{Ion channel modulators}}
{{Ionotropic glutamate receptor modulators}}

[[Category:Sulfonamides]]
[[Category:Vasodilators]]
[[Category:Potassium channel openers]]
[[Category:Benzothiadiazines]]
[[Category:Chloroarenes]]
[[Category:AMPA receptor positive allosteric modulators]]
[[Category:Kainate receptor agonists]]
[[Category:Carbonic anhydrase inhibitors]]